Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Zoetis Inc. (ZTS) filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, enabling the company and future selling securityholders to issue an indeterminate amount of securities, including debt, common and preferred stock, warrants, depositary shares, purchase contracts/units, guarantees and hybrid instruments.
Each issuance will be detailed in a later prospectus supplement; no specific size, price or timing is disclosed in this filing. Net proceeds, when and if raised, may fund general corporate purposes such as working capital, capital expenditures, acquisitions and debt refinancing.
The prospectus summarises indenture terms—pari-passu ranking, optional redemption, covenants limiting certain liens and sale-leasebacks, standard events of default and defeasance options. The company re-confirms its NYSE listing (symbol “ZTS”) and notes 443.9 million common shares outstanding (authorised: 6 billion).
Risk factors are incorporated by reference and cover competitive pressures, supply-chain disruption, economic conditions, regulation, FX volatility and substantial indebtedness. The filing involves no immediate security issuance; it simply preserves capital-raising flexibility.
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.